Home > Insider Trading > Filing (0001209191-21-008750)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1641281	Bolt Biotherapeutics Inc.	BOLT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1245624	James Healy	C/O Bolt Biotherapeutics, Inc. 900 Chesapeake Drive Redwood City CA 94063		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-02-09	1,104,209	$0.00	1,104,209	No	4	C	Indirect	By Sofinnova Venture Partners X, L.P.
Common Stock	Acquisiton	2021-02-09	1,200,228	$0.00	2,304,437	No	4	C	Indirect	By Sofinnova Venture Partners X, L.P.
Common Stock	Acquisiton	2021-02-09	450,000	$20.00	2,754,437	No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	C	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	P	Indirect	By Sofinnova Venture Partners X, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C-1 Preferred Stock	Disposition	2021-02-09	1,104,209	$0.00	1,104,209	$0.00
Common Stock	Series C-2 Preferred Stock	Disposition	2021-02-09	1,200,228	$0.00	1,200,228	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.
The securities reported herein are held of record by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. The Reporting Person is one of three managing members of SM X and may be deemed to have shared voting and dispositive power over the shares held by SVP X. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.
The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.